Robert G. L. Shorr
Gründer bei Cornerstone Pharmaceuticals, Inc.
Profil
Robert G.
L.
Shorr is the founder of AT Biochem, Inc., Cornerstone Pharmaceuticals, Inc., and several other companies.
He currently holds the position of Director-Business Development at Stony Brook University since 1998, Trustee at Imperial College London since 1999, and Trustee at Tissue Engineering Charities, Inc. since 1999.
Previously, he served as Director at BioDelivery Sciences International, Inc., Director at Brainstorm Cell Therapeutics, Inc. from 2011 to 2018, Associate Director at Smithkline & French Laboratories US, Inc. from 1988 to 1988, and President-Research & Development at Enzon Pharmaceuticals, Inc. He also held the position of Vice President-Science & Technology at United Therapeutics Corp.
in 2005.
Dr. Shorr obtained a doctorate degree from the University of London and an undergraduate degree from the State University of New York at Buffalo.
Aktive Positionen von Robert G. L. Shorr
| Unternehmen | Position | Beginn |
|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Gründer | - |
| Stony Brook University | Corporate Officer/Principal | 01.01.1998 |
| Tissue Engineering Charities, Inc. | Direktor/Vorstandsmitglied | 16.05.2011 |
| Imperial College London | Direktor/Vorstandsmitglied | 01.01.1999 |
Ehemalige bekannte Positionen von Robert G. L. Shorr
| Unternehmen | Position | Ende |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.02.2018 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Direktor/Vorstandsmitglied | 28.04.2005 |
| UNITED THERAPEUTICS CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 |
| Smithkline & French Laboratories US, Inc. | Corporate Officer/Principal | 01.01.1988 |
| AT Biochem, Inc. | Gründer | - |
Ausbildung von Robert G. L. Shorr
| University of London | Doctorate Degree |
| State University of New York at Buffalo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Smithkline & French Laboratories US, Inc. | |
| AT Biochem, Inc. | |
| Tissue Engineering Charities, Inc. |
